We developed several adenoviral vectors designed to target MDA-7 expression to different subcellular compartments [endoplasmic reticulum (ER), mitochondria, nucleus, and cytosol] and evaluated their ability to enhance apoptosis. Adenoviral ER-targeted mda-7/interleukin-24 vector (Ad-ER-mda7) selectively and effectively inhibited the growth and proliferation of lung (A549 and H1299) and esophageal (Seg1 and Bic1) cancer cells by enhancing cell killing. Both Ad-mda7 and Ad-
Introduction
The melanoma differentiation-associated gene-7 (mda-7) is a tumor suppressor gene that induces apoptosis in a wide range of cancer cells, both in vivo and in vitro, when overexpressed through a replication-incompetent adenoviral vector (1 -4) . The cytotoxic activity of the mda-7 gene product is specific to tumor cells and independent of the status of other tumor suppressor gene products (e.g., p53, Rb, ras, or p16 INK4 ; ref. 5) . The cDNA of mda-7 encodes an evolutionarily conserved protein (MDA-7) that, despite having only 19% identity with the homodimeric cytokine interleukin (IL)-10, has been assigned to the IL-10 family and renamed IL-24 (6, 7) . This assignment was based on the amino acid identity of MDA-7 with IL-10 and incorporation of an IL-10 family motif, its chromosomal localization within an IL-10 family cluster of genes, its translational regulation, and its predicted structural features (e.g., a fourhelix bundle structure characteristic of the IL-10 family; refs. 6, 7). Ectopic expression of mda-7 in cancer cells by Ad-mda7 or plasmid DNA vectors results in the overproduction of intracellular MDA-7 protein and its secreted form, IL-24 (1, 5) .
In laboratory studies using lung cancer cell lines, we have shown that MDA-7 overexpression leads to the up-regulated expression and phosphorylation of the RNA-dependent protein kinase (PKR) necessary for Admda7-induced apoptosis (8, 9) . In addition, we and others have shown that MDA-7/IL-24 intracellular-mediated apoptosis may involve the endoplasmic reticulum (ER) signaling pathway. For example, we have shown the consistent overexpression of several ER stress proteins (GRP78/BiP, GADD34, and PP2A) in Ad-mda7-treated lung cancer cells (10) . Meanwhile, Fisher's group has shown that the ER chaperone protein GRP78/BiP, by serving as an intracellular target of MDA-7/IL-24 and thereby mediating MDA-7/IL-24's activation of its downstream targets p38 mitogen-activated protein kinase and GADD, selectively mediates apoptosis of prostate and breast cancer cells (11, 12) . Molecular chaperones, such as GRP78/BiP and HSP70, play important roles in the unfolded protein response pathway by preventing the aggregation of misfolded proteins and shuttling them to the 20S proteasome for degradation (13) . Because ER is a principal site for MDA-7/IL-24 protein synthesis and folding (10, 13) , the ER stress-mediated cell death pathway can be triggered by disparate perturbations in normal ER function, such as the accumulation of unfolded, misfolded, or excessive MDA-7/IL-24 protein.
Assuming that Ad-mda7 treatment induces the accumulation of MDA-7 proteins and consequently ER and/or cytoplasmic stress, we hypothesized that the subcellular location (specifically, in the ER) of MDA-7/IL-24 is an important regulator of its antitumor activity. To test this hypothesis, we designed adenoviral vectors that would target MDA-7 expression to different subcellular compartments (ER, mitochondria, nucleus, and cytosol) and compared their ability to induce apoptosis in lung and esophageal cancer cells. Our results indicated that the adenoviral ER-targeted vector induced much higher levels of cell death than did those targeted elsewhere within the cell and that this vector enhanced cell killing. Our results also showed that caspase-4 and JNK activation mediated the apoptosis induced by both untargeted (Ad-mda7) and ER-targeted (Ad-ER-mda7) vectors.
Materials and Methods

Cell Lines and Reagents
Human lung (A549 and H1299) and esophageal (Seg1 and Bic1) cancer cell lines were obtained from the American Type Culture Collection. PKR +/+ and PKR À/À mouse embryo fibroblasts (MEF) were obtained from Dr. Glen Barber (University of Miami School of Medicine; ref. 14) . MEF cells were maintained in DMEM containing 10% fetal bovine serum, 10 mmol/L glutamine, 100 units/mL penicillin, and 100 Ag/mL streptomycin (Life Technologies) in a 5% CO 2 atmosphere at 37jC. Caspase-4 and JNK inhibitors were obtained from Calbiochem. Final working solutions were diluted in medium to contain <0.01% DMSO. All experiments using this compound were done under subdued lighting conditions. Adenoviral Vector Construction Constructions of the Ad-mda7, Ad-LacZ, and Ad-luc vectors have been reported previously (8) . Constructions of plasmids targeted to the ER (pCMV/myc/ER/mda-7), mitochondria (pCMV/myc/Mito/mda-7), nucleus (pCMV/myc/Nuc/mda-7), and cytosol (pCMV/myc/ Cyto/mda-7) have been reported previously (10) . The ER-mda-7 fragment from pCMV/myc/ER/mda-7 was obtained by digestion at the PmII and BclI sites. The Mito-mda-7 fragment from pCMV/myc/Mito/mda-7 was obtained by digestion at the PmII and BclI sites. The Nuc-mda-7 fragment from pCMV/myc/Nuc/mda-7 was obtained by digestion at the HincII and BcII sites. The Cytomda-7 fragment from pCMV/myc/Cyto/mda-7 was obtained by digestion at the HincII and BcII sites.
Individual shuttle vectors were obtained as follows. The PLJ37/pAD-RAP/Shuttle vector was subjected to EcoRV and BcII digestion and ligated with ER-mda7, Mito-mda7, Nuc-mda-7, or Cyto-mda7 fragments to obtain their respective shuttle vectors (PLJ37/pAD-RAP/ER-mda7/ Shuttle vector, PLJ37/pAD-RAP/Mito-mda7/Shuttle vector, PLJ37/pAD-RAP/Nuc-mda7/Shuttle vector, or PLJ37/ pAD-RAP/Cyto-mda7/Shutle vector). The resulting shuttle vectors were then subjected to further digestion with BstBI and CIaI to obtain large fragments. Each of the resulting large fragments was then inserted into a pLJ34 vector between the BstBI and CIaI sites to create adenoviral vectors specifically targeted to the ER, mitochondria, nucleus, and cytosol, respectively (Ad-ER-mda7, Ad-Mitomda7, Ad-Nuc-mda7, and Ad-Cyto-mda7). Adenoviral transduction efficiency in cancer cell lines was determined by infecting cells with Ad-LacZ vectors and quantifying the titers needed to transduce the LacZ gene into at least 70% of the cells.
Immunofluorescent Cellular Localization Studies A549 lung cancer cells (5 Â 10 4 per well) were grown on chamber slides to 70% confluence and then transfected with Ad-luc, Ad-mda7, Ad-ER-mda7, Ad-Mito-mda7, Ad-Nucmda7, or Ad-Cyto-mda7 or treated with PBS as a negative control. Seventy-two hours later, cells were washed with PBS and fixed with 4% paraformaldehyde/PBS for confocal microscopic analysis described as previously (9) . In brief, cells were blocked with 1% normal goat serum for 1 h and then incubated overnight at a dilution of 1:100 with the primary mouse monoclonal anti-MDA-7 antibody. Next, the slides were washed to remove primary antibody, rinsed with PBS, and placed in a prewarmed staining solution containing ER-Tracker red dyes or MitoTracker Deep Red 633 (M-22426; Molecular Probes) for f15 to 20 min at 37jC. Then, the slides were washed and incubated with a FITCor rhodamine-conjugated secondary antibody (Invitrogen) for 1 h. Next, the slides were mounted with ProLong Gold antifade reagent containing 4 ¶,6-diamidino-2-phenylindole (DAPI; Invitrogen) and analyzed under an Olympus FluoView FV500 laser confocal microscope (Olympus America) after adjustment for background staining.
Flow Cytometric Analysis Apoptosis was assessed by propidium iodide staining and fluorescence-activated cell sorting analysis of cells. In brief, cells were harvested, pelleted by centrifugation, resuspended in PBS containing 50 Ag/mL propidium iodide, 0.1% Triton X-100, and 0.1% sodium citrate, vortexed, and then subjected to fluorescence-activated cell sorting analysis (Becton Dickinson FACScan; FL-3 channel).
Immunoblot Analyses Seventy-two hours after adenoviral transfection, A549 or H1299 cell extracts were prepared and immunoblot assays were done as described previously (8, 9) . Antibodies to JNK, phosphorylated JNK (p-JNK), c-Jun, phosphorylated c-Jun, PKR (K-17), eIF-2a, and h-actin (control) were obtained from Santa Cruz Biotechnology. The caspase-4 was obtained from StressGen. Antibodies to phosphorylated PKR (pT451) and phosphorylated eIF-2a (Ser 51 ) were obtained from BioSource International. Polyclonal and monoclonal antibodies to MDA-7 were obtained from Introgen Therapeutics.
Analysis of In vivo Tumor Growth after Ad-mda7 or Ad-ER-mda7 Treatment A549 cells (5 Â 10 6 per 0.2 mL) were injected s.c. into the flanks of female athymic nu/nu mice 4 to 6 weeks old. Once a tumor grew to f5 Â 5 mm, PBS, Ad-luc, Ad-mda7, or Ad-ER-mda7 was injected directly into it via a single pass of a 25-gauge hypodermic needle at dose of 3 Â 10 12 viral particles (vp). A second injection was given 3 days later and a third injection 3 days after that. Thus, each mouse received a total of three injections (total 9 Â 10 12 vp) over 6 days. After the third injection, the maximal and minimal diameters of each tumor were measured by slide calipers placed on the skin, every 2 days for 30 days. Tumor volume was calculated by assuming a spherical shape and using the following formula: volume = (a Â b 2 ) / 2, where a and b are the maximal and minimal diameters, respectively. Results for each treatment group (6-9 mice per group) were averaged and expressed as the mean (SD).
Apoptosis was measured by histologic analysis. In brief, tumors were excised 24 h after the third injection in vivo, fixed in 10% formalin, embedded in paraffin blocks, and processed for histologic analysis and terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling assays. For terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling assay, sections were dewaxed, rehydrated (55jC for 15 min), washed in xylene, and then rehydrated through a graded series of ethanol and redistilled water. Tissue sections were then incubated with proteinase K, permeabilized in 0.1% Triton X-100 in 0.1% sodium citrate, and labeled with the terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling reaction mixture.
Statistical Analysis ANOVA and a two-tailed Student's t test were used for statistical analysis when appropriate. Significance was set at P < 0.05.
Results
Mda-7 Adenoviral Vectors Induce Targeted Intracellular Expression of MDA-7 Protein
As confirmed by immunofluorescent confocal microscopic analysis of A549 lung cancer cells 72 h after transfection, the adenovirus-mediated intracellular targeting vectors Ad-ER-mda7, Ad-Mito-mda7, Ad-Nuc-mda7, and Ad-Cyto-mda7 successfully targeted MDA-7 protein expression to specific subcellular regions of the transduced cancer cells (Fig. 1A) . The precise subcellular localization of the targeted proteins was confirmed by comparison of their expression patterns with those of molecular markers known to reside in these compartments. For example, nuclear targeted MDA-7 colocalized with DAPI-stained nuclei, and ER-targeted MDA-7 colocalized with ERTracker red dye. To determine whether these intracellularly As shown by flow cytometric analysis of human lung (A549 and H1299) and esophageal (Seg1 and Bic-1) cancer cells after transfection, all of the intracellularly targeted mda-7 adenoviral vectors, except Ad-Nuc-mda7 vector, induced cell death within 72 h of transfection ( Fig. 2A) . Of those vectors that did induce apoptosis, the ER-targeted MDA-7 adenoviral vector (Ad-ER-mda7) was much more lethal than either mitochondria-targeted (Ad-Mito-mda7) or cytosol-targeted mda-7 (Ad-Cyto-mda7) vectors and also more lethal than the untargeted mda-7 vector (Ad-mda7). Moreover, as shown by flow cytometric analysis of NHBE normal human bronchial epithelial cells and WI-38 normal human fibroblasts 72 h after their adenoviral exposure, only one of the intracellularly targeted adenoviral mda7 vectors (Ad-Mito-mda7) was toxic to normal cells ( Fig. 2A) .
We hypothesize that the ER stress (accumulation of MDA-7 proteins in ER) is essential to Ad-ER-mda7-mediated cell death activity in cancer cells. To test our hypothesis, we determined the most important ER stress markers (JNK, p-JNK, c-Jun, and phosphorylated c-Jun) in A549 and H1299 lung cancer cells following PBS, Ad-mda7, Ad-ER-mda7, Ad-Mito-mda7, Ad-Nuc-mda7, and AdCyto-mda7 treatment for 72 h by immunoblot analysis (15) . As shown in Fig. 2B , expression of p-JNK and phosphorylated c-Jun was up-regulated after Ad-mda7 and Ad-ER-mda7 transduction but not after Ad-Mitomda7, Ad-Nuc-mda7, or Ad-Cyto-mda7 transduction (Fig. 2B) , suggesting that activation of JNK or c-JUN was the mechanism by which Ad-mda7-and Ad-ER-mda7-mediated cell killing.. Caspase-4 is an ER-resident caspase that is processed in human cells in response to ER stress and is required for ER stress-induced cell death (15) . We next investigated whether caspase-4 was involved in Ad-mda7-and Ad-ER-mda7-induced cell death. Caspase-4 was cleaved to its active form in A549 and H1299 human lung cancer cells treated with Ad-mda7 or Ad-ER-mda7 but not in those treated with Ad-Mito-mda7, Ad-Nuc-mda7, or Ad-Cyto-mda7 (Fig. 2B) . To more directly determine the importance of JNK and caspase-4 activation to Ad-mda7-and Ad-ER-mda7-mediated cell death, A549 cells were exposed to Ad-mda7 and Ad-ER-mda7 in the absence or presence of a chemical JNK inhibitor (SP600125, 10 Amol/L) or a peptide inhibitor of caspase-4 (Ac-LEVD-CHO, 10 Amol/L) and subjected to fluorescence-activated cell sorting analysis to determine the extent of the resulting cell death. In both case, inhibitory treatment reduced the amount of cell death induced by both Ad-mda7 (from 22.3% to 17% after JNK inhibition and from 22.3% to 13% after caspase-4 inhibition) and Ad-ER-mda7 (from 52% to 41% after JNK inhibition and from 52% to 27% after caspase-4 inhibition; Supplementary Data S1). 4 Conversely, neither inhibitor reduced the amount of cell death induced by Ad-Mito-mda7 or Ad-Cyto-mda7 (Supplementary Data S1). 4 Together, this suggested that both Ad-mda7-and Ad-ER-mda7-mediated cell killing involved the activation of JNK and caspase-4.
We have shown that MDA-7 overexpression in human lung cancer cells leads to the up-regulation and phosphorylation of PKR necessary for Ad-mda7-induced apoptosis (8, 9) . We next determined if PKR activation might also play a role in Ad-ER-mda7-infected cancer cells. Human lung cancer cells revealed that both Ad-mda7 and Ad-ERmda7 up-regulated and promoted the phosphorylation of PKR (Fig. 2B) . In contrast, Ad-Mito-mda7, Ad-Nuc-mda7, and Ad-Cyto-mda7 did not. This contribution of PKR activation to the apoptotic activity of Ad-ER-mda7 was confirmed in experiments using MEF from PKR knockout mice. That Ad-mda7-induced cell killing was dependent on PKR was confirmed by the fact that only MEF from PKR +/+ (wild-type) mice underwent apoptosis induction after Ad-mda7 treatment (Supplementary Data S2; 4 ref. 8 ). Ad-ER-mda7-mediated cell killing was also dependent on PKR with background level of apoptosis occurring in PKRnull and 20% apoptosis occurring in wild-type MEF (Supplementary Data S2). 4 Conversely, neither Ad-Mitomda7-nor Ad-Cyto-mda7-induced apoptosis appeared to be dependent on PKR genomic status, apoptosis occurring at similar rates in both PKR À/À and PKR +/+ MEF (Supplementary Data S2). 4 In vivo Regression of Tumors Follows Intratumoral Injection of Ad-mda7 or Ad-ER-mda7 in nu/nu Mice As shown by in vivo experiments in a s.c. nu/nu tumor mouse model and in confirmation of previous studies showing that intratumoral administration of Ad-mda7 inhibits the growth of lung tumor xenografts (16), intratumorally injected Ad-mda7 and Ad-ER-mda7 were both significantly more growth inhibitory than either PBS or Ad-luc [controls; P = 0.01 (Ad-mda7) and P = 0.005 (Ad-ER-mda7) versus controls; Fig. 3A ]. In addition, intratumorally injected Ad-ER-mda7 was significantly more growth inhibitory than Ad-mda7 (P = 0.02; Fig. 3A) . No significant tumor inhibition was observed in either Ad-luc-or PBS-treated mice. Analysis of A549 lung tumor tissue showed that (a) the growth inhibition observed in Figure 3 . In vivo regression of tumors after intratumoral injection of Ad-mda7 or Ad-ER-mda7 in nu/nu mice. A, A549 tumor growth was significantly inhibited after injection with Ad-mda7 or Ad-ER-mda7 as opposed to PBS or Ad-luc. In each case, mice received a total of three injections over 6 d.
Tumor volumes (Y axis) were measured in six to nine mice per group over 30 d. Mean (SD). B, histology of A549 tumors 24 h after last treatment with PBS, Ad-luc, Ad-mda7, or Ad-ER-mda7 (H&E staining; magnification, Â40). Analysis of A549 lung tumor tissues showed that the growth inhibition observed in Ad-mda7-or Ad-ER-mda7-treated mice was caused by MDA-7 protein expression and apoptosis. In addition, MDA-7 protein expression was associated with increased p-JNK and PKR expression in tumor tissues treated with Ad-mda7 or Ad-ER-mda7 as opposed to controls (PBS or Ad-luc).
Ad-mda7-or Ad-ER-mda7-treated mice was caused by MDA-7 protein expression and (b) this MDA-7 protein expression in both cases was associated with higher levels of p-JNK and PKR expression than those seen in control tumor tissues (Fig. 3B) . Terminal deoxynucleotidyl transferasemediated dUTP nick end labeling assays showed increased terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling -positive staining cells in Ad-mda7-or Ad-ER-mda7-treated mice tissue (Fig. 3B) . Thus, Ad-ERmda7 effectively inhibited lung tumor growth in vivo, and intratumoral injection of Ad-mda7 or Ad-ER-mda7 caused no significant systemic toxicity. Together, these results showed the potential antitumor effect of Ad-mda7 or Ad-ER-mda7 when injected directly into tumors.
Discussion
In the present study, we have shown that Ad-mda7 or Ad-ER-mda7 treatment results in ER stress-induced apoptosis. We have also shown that Ad-mda7-or Ad-ER-mda7-mediated growth inhibition in vivo correlates with the activation of ER molecular markers such as PKR and JNK observed in vitro in Ad-mda7-or Ad-ER-mda7-treated cancer cells.
The replication-incompetent adenoviral vector Ad-mda7 is minimally toxic to normal cells but a potent inducer of apoptosis in a variety of cancer cell lines (1 -5). As we and our collaborators have shown, mda-7 gene transfer via Ad-mda7 induces tumor-specific apoptotic, growth-inhibitory, and antiangiogenic effects independently of the status of other tumor suppressor genes (12, 17 -19) . In addition to its direct cytotoxic effects, Ad-mda7 transduction elicits the secretion of MDA-7, a protein that is also known as IL-24 and has unique apoptotic properties (21, 20, 21) . In phase I trials in patients resistant to conventional therapy, intratumoral Ad-mda7 injection has produced minimal adverse effects and exhibited clinical activity in a subset of patients heavily pretreated with chemotherapeutics and radiation (22). Previously, we have shown that Admda7 transduction of human lung cancer cells can increase expression of stress-related proteins, including GRP78/BiP, GADD34, PP2A, caspase-7, and XBP-1, consistent with activation of the unfolded protein response pathway, a key sensor of ER-mediated stress (23) . The unfolded protein response pathway is an ER-to-nucleus signal transduction pathway that regulates the expression of a wide variety of target genes and is responsible for maintaining cellular homeostasis (13) . Thus, activation of unfolded protein response signaling appears to be important in mediating apoptosis induced by Ad-mda7.
In the present study, we used a set of intracellularly targeted mda-7 adenoviral vectors that we designed to drive the expression of protein in specific subcellular compartments (ER, mitochondria, nucleus, and cytoplasm). Of all these vectors, the ER-targeted Ad-ER-mda7 vector was by far the most lethal to cells.
Interestingly, our demonstration that Ad-ER-mda7 transduction can still induce the secretion of MDA-7 protein warrants further studies to determine whether a secreted extracellular form from Ad-ER-mda7 could induce STAT3 activation and apoptosis in cancer cells. Indeed, after Ad-mda7 transduction of lung cancer cells, MDA-7 protein exists in both an intracellular form and a secreted extracellular form (1) . The secreted extracellular form can bind to two different receptors: the type 1 IL-20 heterodimeric receptor complex comprising IL-20R1/IL-20R2 and the type 2 complex comprising IL-22R1/IL-20R2, which leads to activation of the STAT signaling pathways (12) .
We next examined the expression of several downstream proteins including JNK, c-Jun, and caspase-4. The ER stress-mediated cell death pathway involves recruitment of the cytosolic adaptor TRAF2 to the ER membrane, where TRAF2 activates the apoptosis signaling kinase 1. Activation of apoptosis signaling kinase 1 leads in turn to activation of JNK and mitochondria-dependent caspase (24) . Meanwhile, human caspase-4, which is 48% homologous to murine caspase-12, has been shown to be localized to the ER membrane and to be specifically activated by and required for ER stress-induced apoptosis (13) . In this light, we showed that JNK and c-Jun activation is essential for Ad-mda7-and Ad-ER-mda7-mediated cell death, that Ad-mda7 and Ad-ER-mda7 treatment induces caspase-4 cleavage, and that p-JNK and caspase-4 are major drivers of apoptosis in Ad-mda7-and Ad-ER-mda7-transduced A549 lung cancer cells. Like Ad-mda7, which has been reported to use caspase-dependent and caspase-independent pathways of activation (8) , our studies suggest that Ad-ER-mda7-induced apoptosis is partially dependent on caspase. Taken together, our data indicate that induction of ER stress-induced apoptosis by JNK and caspase-4 mediates Ad-mda7-and Ad-ER-mda7-induced apoptosis.
PKR is well characterized in the literature as an antiviral immune mediator that responds to viral dsRNA by activating eIF-2a, inhibiting protein synthesis inhibition, and blocking viral protein production (25) . Apparently, its activation in HeLa, Cos1, U937, and NIH3T3 tumor cells leads to apoptosis induction (26, 27) . Building on our previous demonstrations that Ad-mda7 transfection of lung cancer cells leads to the up-regulation and phosphorylation of PKR necessary for Ad-mda7-induced apoptosis (8, 9), we have now shown that Ad-ER-mda7 transduction does the same. We also found that up-regulation and phosphorylation of PKR is specific for Ad-mda7 and Ad-ER-mda7 because we saw no change in PKR expression after transduction with Ad-Mito-mda7, Ad-Nuc-mda7, or Ad-Cyto-mda7. In turn, we also conclude that the PKR up-regulation and phosphorylation induced by Ad-mda7 and Ad-ER-mda7 is not solely a response to adenoviral transfection because all of the other vectors we tested failed to induce PKR induction. Indeed, PKR induction appears to be critical for Ad-mda7 or Ad-ER-mda7 apoptosis because normal MEF lacking PKR were unable to undergo apoptosis as opposed to MEF-expressing wild-type PKR. This inhibition of apoptosis appeared to be specific to both Ad-mda7 and Ad-ER-mda7 because transduction of MEF lacking PKR with the Ad-Mito-mda7 vector did not impair apoptosis. In light of our previous identification of MDA-7 as a novel binding partner for PKR (9) , further study is warranted to determine whether Ad-ER-mda7-induced MDA-7 might also interact with PKR.
Ad-ER-mda7 appears to be extremely growth inhibitory. This was shown by our experiments in an in vivo xenograft tumor model in which intratumoral administration of Admda7 or Ad-ER-mda7 in mice bearing s.c. tumors significantly inhibited tumor growth and by tumor tissue studies showing an association between MDA-7 protein expression and the increased induction of PKR and p-JNK expression in Ad-mda7-or Ad-ER-mda7-treated tumor tissue as opposed to untreated (control) tissues.
In summary, by targeting the ER, Ad-ER-mda7 can induce cell death to a much greater extent through the ER stress-mediated cell death pathway involving caspase-4, JNK, and PKR activation. Ad-mda7 or Ad-ER-mda7 treatment results in ER stress-induced apoptosis and tumor growth inhibition in vivo. Going forward, our preliminary identification of the molecular mechanisms responsible for Ad-mda7-induced apoptosis of human cancer cells bodes well for the rational development of strategies for enhancing the antitumor effects of MDA-7, and our development of intracellularly targeted mda-7 adenoviral vectors will allow for the clinical optimization of this gene transfer therapy and the identification of patients unresponsive to Ad-mda7 therapies who might benefit from targeted therapy. 
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